Improved outcome in relapsed and refractory myeloid malignancies for unrelated vs related donor allogeneic peripheral blood-derived hematopoietic cell transplantation

Bone Marrow Transplantation

Volumn 45, Issue 8, 2010, Pages 1309-1315

  Denz, U ^a   Bertz, H ^a   Ihorst, G ^b   Wasch R ^a   Finke, J ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

allogeneic cell transplantation; AML; GVHD; myelodysplastic syndrome

Indexed keywords

ATG F; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; BACTERIAL PNEUMONIA; CONTROLLED STUDY; CONVULSION; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HEMOLYSIS; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER DISEASE; LIVER TOXICITY; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; SKIN TOXICITY; TREATMENT RESPONSE; TUBERCULOSIS; VIRUS PNEUMONIA;

ADOLESCENT; ADULT; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955588196     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.341     Document Type: Article

References (31)

1. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909-1918.
2. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341: 1051-1062.
3. Sierra J, Storer B, Hansen JA, Martin PJ, Petersdorf EW, Woolfrey A et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant 2000; 26: 397-404. (Pubitemid 30649555)
4. Ferrant A, Labopin M, Frassoni F, Prentice HG, Cahn JY, Blaise D et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood 1997; 90: 2931-2938.
5. Gale RP, Horowitz MM, Weiner RS, Ash RC, Atkinson K, Babu R et al. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplant 1995; 16: 203-208.
6. Greinix HT, Nachbaur D, Krieger O, Eibl M, Knobl P, Kalhs P et al. Factors affecting long-term outcome after allogeneic haematopoietic stem cell transplantation for acute myelogenous leukaemia: a retrospective study of 172 adult patients reported to the Austrian Stem Cell Transplantation Registry. Br J Haematol 2002; 117: 914-923.
7. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325-4336.
8. Visani G, Bernasconi P, Boni M, Castoldi GL, Ciolli S, Clavio M et al. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia-analysis of 848 patients. Leukemia 2001; 15: 903-909.
9. Bertz H, Potthoff K, Mertelsmann R, Finke J. Busulfan/ cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity. Bone Marrow Transplant 1997; 19: 1169-1173.
10. Przepiorka D, Chan KW, Champlin RE, Culbert SJ, Petropoulos D, Ippoliti C et al. Prevention of graft-versus- host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients. Bone Marrow Transplant 1995; 16: 737-741.
11. Sullivan KM, Shulman HM, Storb R, Weiden PL, With- erspoon RP, McDonald GB et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267-276.
12. Bacigalupo A, Lamparelli T, Gualandi F, Bregante S, Raiola AM, Di Grazia C et al. Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants. Biol Blood Marrow Transplant 2002; 8: 656-661.
13. McGlave PB, Shu XO, Wen W, Anasetti C, Nademanee A, Champlin R et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood 2000; 95: 2219-2225.
14. Petersdorf EW, Longton GM, Anasetti C, Martin PJ, Mickelson EM, Smith AG et al. The significance of HLA- DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 1995; 86: 1606-1613.
15. Finke J, Schmoor C, Lang H, Potthoff K, Bertz H. Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin. J Clin Oncol 2003; 21: 506-513.
16. Bacigalupo A. Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplant 2005; 35: 225-231.
17. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009; 10: 855-864.
18. Tallman MS, Dewald GW, Gandham S, Logan BR, Keating A, Lazarus HM et al. Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood 2007; 110: 409-417.
19. Cook G, Clark RE, Crawley C, Mackinnon S, Russell N, Thomson K et al. The outcome of sibling and unrelated donor allogeneic stem cell transplantation in adult patients with acute myeloid leukemia in first remission who were initially refractory to first induction chemotherapy. Biol Blood Marrow Transplant 2006; 12: 293-300.
20. Yakoub-Agha I, Mesnil F, Kuentz M, Boiron JM, Ifrah N, Milpied N et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 2006; 24: 5695-5702.
21. Singhal S, Powles R, Henslee-Downey PJ, Chiang KY, Treleaven J, Godder K et al. Allogeneic transplantation from HLA-matched sibling or partially HLA-mismatched related donors for primary refractory acute leukemia. Bone Marrow Transplant 2002; 29: 291-295.
22. Fung HC, Stein A, Slovak M, O'Donnell MR, Snyder DS, Cohen S et al. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. Biol Blood Marrow Transplant 2003; 9: 766-771.
23. Alyea EP, Kim HT, Ho V, Cutler C, DeAngelo DJ, Stone R et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 2006; 12: 1047-1055.
24. Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 2007; 109: 3658-3666.
25. Lee JH, Choi SJ, Seol M, Lee YS, Ryu SG, Park CJ et al. Anti- leukemic effect of graft-versus-host disease on bone marrow and extramedullary relapses in acute leukemia. Haematologica 2005; 90: 1380-1388.
26. Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodys- plastic syndrome. Blood 2002; 100: 1201-1207.
27. Frassoni F. Randomised studies in acute myeloid leukaemia: the double truth. Bone Marrow Transplant 2000; 25: 471-473.
28. Marks DI, Bird JM, Vettenranta K, Hunt L, Green A, Cornish JM et al. T cell-depleted unrelated donor bone marrow transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant 2000; 6: 646-653.
29. Ringden O, Pavletic SZ, Anasetti C, Barrett AJ, Wang T, Wang D et al. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoie- tic stem cell transplantation. Blood 2009; 113: 3110-3118.
30. Heining C, Spyridonidis A, Bernhardt E, Schulte-Monting J, Behringer D, Grullich C et al. Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: a retrospective study including 148 patients. Bone Marrow Transplant 2007; 39: 613-622.
31. Schetelig J, Bornhauser M, Schmid C, Hertenstein B, Schwerdtfeger R, Martin H et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J Clin Oncol 2008; 26: 5183-5191.